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Table 1
AML- Acutemyeloid leukemia; HLH - Hemophagocytic lymphohistiocytosis;
ALL- Acute lymphocytic leukemia; CR e Complete remission; N/A e Not
applicable.
Patient Characteristics
(Numbers)
Diagnosis
AML 8
HLH 1
MDS 3
ALL 2
Disease Status
CR 11
N/A 3
Regimen 9
IV BU/ IV Flu IV BU/ IV Flu + Thymoglobulin
(1.5 mg/kg (T-3 to T-1)
5
Regimen Intensity
AUC 6000 8
AUC 4500 1
AUC 4000 5
Donors
Related 5
Unrelated 9
HLA Match
9/10 2
10/10 12
Median (Range)
CD34 Cells Infused (cells/kg) 7 (2.7-15)
Age at the time of transplant (years) 48.5 (23-61)
Body Surface Area (m2) 1.825 (1.5 e 2.1)
AUC Achieved prior to PK adjustment
(micromole/min)
6000 4482.5 (3652 - 5771)
4000 3221 (2556 - 4579)
Overall AUC Achieved (micromole/min)
6000 5380.5 (4821 - 5978)
4000 4004 (3732 - 4155)
Dose Adjustment
6000 339 (252 - 460)
4000 240 (150 - 273)
Time to Achieve Engraftment (days)
ANC > 500 k/uL 15 (11-20)
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and rejection in hematopoietic cell transplantation (HCT),
children receive anti-thymocyte globulin (ATG), a polyclonal
antibody depleting T-cells, as part of the conditioning
regimen. The therapeutic window is critical as over-exposure
may result in delayed reconstitution of donor T-cells and
increased risk of viral infections. Our objective is to describe
the population pharmacokinetics (PK) of Thymoglobulin as a
ﬁrst step towards an evidence based dosing regimen of
Thymoglobulin for HCT in children.
Methods: PK data were collected for all pediatric HCT’s per-
formed between 2004-2012 in two study centers in the
Netherlands. Serum active Thymoglobulin concentrations
were quantiﬁed by ﬂow cytometry investigating the binding
to a T-cell line. Population modeling and covariate analysis
was performed on active Thymoglobulin concentrations using
NONMEM 7.2. The ﬁnal model was internally validated using
advanced methods such as bootstrap resampling and NPDE.
Results: A total of 196 HCT’s in 183 patients were analyzed
(table 1). A two-compartment model yielded a good
description of the data in all age groups (ﬁgure 1 and 2),
with no evidence for non-linear elimination. The population
value (SE) for clearance (Cl) and volume of distribution (Vd)
of a median individual of 21 kg was 3.4 (0.2) L/day and 8.4
(0.6) L, respectively, with body weight as a signiﬁcant
covariate. The relationship between bodyweight and both Cl
and Vd was best described by a power function with an
exponent of 0.47 (0.08) and 0.62 (0.07), respectively.
Terminal half-life was 4.9 days-1. Figure 3 illustrates that the
currently used dosing regimen of 10 mg/kg leads to higher
exposure in older children compared to younger children.
Conclusion: In the validated population PK model for active
Thymoglobulin in children, clearance and volume of distri-
bution proved dependent on body weight in a nonlinear
manner. Therefore, childrenwith a higher weight are exposed
to higher concentrations compared to lowerweight children if
the currently used dosing regimen of 10 mg/kg bodyweight is
used. Once the optimal therapeutic window is determined in
pharmacodynamic studies, individualized (weight based)
dosing guidelines of Thymoglobulin can be derived leading to
better outcome after pediatric HCT.113
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Background: IV BU overcomes the wide variation in
achieving steady state drug concentration associated with its
oral administration. Many institutions are limited in using IV
BU because of an inability to perform PK analysis at an
institutional level. At Markey Cancer Center we utilized a
unique strategy for administering IV BU in order to facilitate
PK analysis at an off-site laboratory.
Methods: This is a retrospective, chart review of 14 patients
admitted for allogeneic stem cell transplant between
November 2012 - September 2013 who received a condi-
tioning regimen of IV BU and IV ﬂu. Flu (30 mg/m2) was
administered daily on days T-7 through T-3. BU dosing
(desired area under the curve (AUC)) was determined based
on patient age and performance status based per physiciandiscretion. BU PK calculations were performed by the Seattle
Cancer Care Alliance Pharmacokinetics Laboratory, Seattle,
WA. Growth factors were not used. Patients received a once-
daily BU dose (based on BSA) on days T-7 and T-5. On day T-7,
BU levels were collected at the end of the infusion, 15 mi-
nutes after completion of the infusion, and at 4, 5 ,6, and 8
hours after the start of infusion. Patients did not receive BU
on day T-6 in order to facilitate the ability to use PK analysis
to adjust the last two BU doses on T-4 and T-3.
Results: Patient characteristics are described in Table 1. The
median BU AUC achieved for the myeloabalative group was
5380.5 (4821 - 5978) uMol/min and reduced intensity
group was 4004 (3732 - 4155) uMol/min. Acute GVHD was
observed in six and chronic in two patients. Two patients
also developed cytomegalovirus related disease. One patient
relapsed at day 88 with 4% blasts on bone marrow biopsy.
After a median follow up 176 days all patients are alive.
Conclusions: Our results demonstrate that PK-guided IV BU-
based conditioning regimens could be used in institutions
where the ability to perform institutional PK is not present.
More patients and longer follow-up time would be required
to conclusively determine the effectiveness of this approach.114
Efﬁcacy of Late Hematopoietic Stem Cell Mobilization 35-
40 Hours after Administration of Plerixafor
Vikas Bhushan 1, Jennifer Potter 1, Katherine Sellers 1,
Marchelle Badon 2, Maria Custodio 2, Diane Ingermann 2,
Abstracts / Biol Blood Marrow Transplant 20 (2014) S91eS103 S99Jennifer Kurre 2, Arida Lulo 2, David Samuel 2. 1 Bone Marrow
Transplantation, Texas Oncology, PA, Dallas, TX; 2Medical City
Dallas Hospital, Dallas, TX
Background: Plerixafor with granulocyte stimulating factor
(G-CSF) is effective for Peripheral Blood CD34+ stem cell
(PBSC) mobilization in patients with poor marrow reserve.
Plerixafor labeling requires administration 11 hours (hrs)
before apheresis. Studies show administration of Plerixafor +
G-CSF results in peak PBSC concentration 10-14 hrs later.
Limited data is available on PBSC count beyond the 14 hr
period, though a recent study showed successful mobiliza-
tion 17 hrs after administration. This allows for a convenient
afternoon dosing for apheresis the next morning. There is no
data on the effect of Plerixafor on PBSC collection beyond the
day after drug administration.
Methods: We studied PBSC collection in seven patients with
diagnosis of Multiple Myeloma(5) or NHL (2) who received
Plerixafor for low PBSC count < 10/ml (5) or low PBSC
collection despite CD34+ count >10/ml(2). All patients had
been heavily pretreated with 3 chemotherapy regimens (6/
7) or had received chemotherapy associated with high risk of
mobilization failure (1/7). Mobilization regimen consisted of
G-CSF (1), Cyclophosphamide + GCSF (1) or combination
chemotherapy + GCSF (5). Patients failing collection received
Plerixafor 0.24mg/kg s/c with G-CSF at 10mcg/kg s/c daily
with apheresis 11- 16 hrs later till target PBSC count was
obtained. Patients then received G-CSF at 10mcg/kg s/c
without Plerixafor and underwent another apheresis the
following day 35-40 hrs after administration of last dose of
Plerixafor.
Results: Patients received Plerixafor beginning day 15-19 in
patients receiving combination chemotherapy, day 14 in
patient receiving Cyclophosphamide and day 6 in patient
receiving G-CSF alone. Total number of Plerixafor dose(s)
received for each patient was 1 to 4 (median 3). Average daily
collection 11-16 hrs post Plerixafor + G-CSF for individual
patients ranged from 0.49 to 4.21 PBSC/kg/day with a mean
of 1.20 PBSC/kg/day. PBSC collection 11-16 hrs after the last
dose of Plerixafor + GCSF ranged from 0.37 to 4.21 PBSC/kg
(mean 2.01). Collection 35-40 hrs post last dose of Plerixafor
ranged from 0.41 to 5.25 PBSC /kg (mean 2.35). All patientsFig 1. Genotype directed initial Voriconazole dosingcollected more PBSC in the 35-40 hr time frame compared to
the 11-16 hr period. The increment in collection in the 35-40
hr period was from 0.01 PBSC/kg to 1.04 PBSC/kg with a
mean increase of 0.34 PBSC/kg. The patient who received G-
CSF alone with no chemotherapy, collections 11 hrs and 35
hrs post Plerixafor were 0.73 PBSC/kg and 1.40 PBSC/kg
respectively.
Discussion: Successful hematopoietic stem cell mobilization
with G-CSF alone was obtained 35-40 hrs beyond last dose of
Plerixafor administration. There is need for further phar-
macodynamic studies on Plerixafor and CD34+ cell count
beyond the conventional 11-14 hr window. Temporal ad-
justments in Plerixafor administration can result in signiﬁ-
cant cost savings and improved convenience in PBSC
mobilization.115
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Background: Invasive fungal infections are a signiﬁcant
cause of morbidity and mortality in recipients of hemato-
poietic cell transplantation (HSCT), warranting antifungal
prophylaxis as a standard of care in these patients. Due to its
broad spectrum activity and multiple available dosage
forms, voriconazole remains one of the commonly usedand subsequent dose adjustment algorithm
